Immatics

Developer of T -cell-based immunotherapies for the treatment of cancer

placeTubingen, Baden Wurttemberg, Germany calendar_todayFounded 2000 groups198 employees language immatics.com

Registered entities

Social engagement

Social engagement: 31.8K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

20 investors on record; lead investors include Wellington Partners Venture Capital, 3i Group, Dievini, DH Capital; 3 have since exited.

Investor typeCountShare
Venture capital1050%
Private equity420%
Accelerator & incubator15%
Bank & private debt15%
Other / undisclosed420%

Hiring activity

Hires periodically

8 roles tracked across 4 of the last 12 months

2 Mar 2026 · Principal Manufacturing Associate - Team Lead - Second Shift · Houston

14 Feb 2026 · Operational Quality Assurance Specialist II · Stafford

13 Nov 2025 · Master Data Management Analyst III · Houston

6 Nov 2025 · Clinical Trial Manager · Indianapolis

22 Oct 2025 · Materials Management and Logistics Specialist II · Houston

Based on job postings tracked across public sources.

Recent activity

24 Jun 2026
Event
BIOSML Symposium
3 Jun 2026
Event
BiotechTV
1 Jun 2026
Event
ASCO26 oral presentation
Coming soon